Atrium Therapeutics, Inc. · NASDAQ:RNA
Atrium Therapeutics — Investor Presentation (August 2026)
27 slides from Atrium Therapeutics's investor presentation, August 2026
Slide 1: Atrium Therapeutics
Atrium Therapeutics August 2026 RNA www.atriumtherapeutics.com LISTED NASDAQ 1
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements FORWARD LOOKING STATEMENTS AND OTHER INFORMATION: Certain statements in this Presentation may constitute “forward - looking statem ents” for purposes of the federal securities laws. Our forward - looking statements include, but are not limited to
Slide 3: Our vision: To pioneer precision RNA medicines for the heart
Our vision: To pioneer precision RNA medicines for the heart and profoundly improve the lives of people impacted by cardiac diseases Our vision: To pioneer precision RNA medicines for the heart and profoundly improve the lives of people impacted by cardiac diseases 3
Slide 4: Atrium has made solid progress since our launch in February 2026
Atrium has made solid progress since our launch in February 2026 KEY MILESTONES • ATR 1072 IND clearance • Announced Phase 1/2 clinical trial – Corventis PRKAG2 syndrome patient identification – build bottom - up view of full patient population ATR 1072 & ATR 1086 – expand into additional cardiomyop
Slide 5: Atrium is at the forefront of genetic cardiomyopathy treatment, and we're moving fast
Atrium is at the forefront of genetic cardiomyopathy treatment, and we're moving fast Patients and physicians are looking for more effective treatment options for genetic cardiomyopathies, and the market is primed for precision therapies Rare Cardiac Proven Ability Targeted Disease with High to Exec
Slide 6: A precision RNA platform primed for genetic cardiomyopathies
A precision RNA platform primed for genetic cardiomyopathies Monoclonal Oligonucleotide Antibody Oligonucleotide Antibodies Therapies Conjugate (AOC) OLIGO mAb mAb OLIGO Targeted Delivery Genetic Precision Scalable Platform ✓ RNA delivery technology designed ✓ Designed to directly target ✓ AOCs appl
Slide 7: Leadership team expertise in rare disease and RNA
Leadership team expertise in rare disease and RNA Leadership team expertise in rare disease and RNA Kath Gallagher | Chief Executive Officer and Board Member Rocio Martin | Chief Strategy Officer 20+ years in the biopharmaceutical industry leading portfolio strategy, 20+ years in various senior stra
Slide 8: Robust wholly-owned pipeline supported by strong capital position
Robust wholly - owned pipeline supported by strong capital position CLINICAL ANTICIPATED UPCOMING TARGET RESEARCH IND- ENABLING PHASE 1 PHASE 2 PHASE 3 MILESTONES Corventis Ph 1/2 PRKAG2 syndrome PRKAG2 ATR 1072 first patient in (FPI) by end of 2026 IND filing PLN cardiomyopathy PLN ATR 1086 in 2027
Slide 9: About Genetic Cardiomyopathies
About Genetic Cardiomyopathies 9
Slide 10: Millions of people with genetic cardiomyopathies lack disease-modifying treatments
Millions of people with genetic cardiomyopathies lack disease - modifying treatments Approximately 1% of patients with genetically driven cardiomyopathies are getting genetic testing1 ~2 Million 50% diagnosed in the US 2 have underlying genetic Most managed through driver of disease 3,4 symptom cont
Slide 11: Three phenotypes across the genetic cardiomyopathy spectrum
Three phenotypes across the genetic cardiomyopathy spectrum Changes in cardiac structure and function can present independently and in combination Hypertrophic Dilated Arrhythmogenic Cardiomyopathy Cardiomyopathy Cardiomyopathy (HCM) (DCM) (ACM) Dyspnea, chest pain, palpitations, syncope Fatigue, ex
Slide 12: ATR 1072 PRKAG2 Syndrome
ATR1072 PRKAG2 Syndrome ATRIUM
Slide 13: PRKAG2 Syndrome
PRKAG2 Syndrome A rare, progressive disease that can lead to sudden cardiac death • Autosomal dominant disease caused by gene mutations in PRKAG2 that leads to AMPK overactivity 0 resulting in glycogen accumulation in heart muscle Approved therapies • Contributes to cardiomyopathy due to thickened h
Slide 14: PRKAG2 syndrome prevalence likely exceeds our initial estimate
PRKAG2 syndrome prevalence likely exceeds our initial estimate This work continues, building towards a confident view of the full population Patient identification strategy is Early findings to uncover the focused in three areas already diagnosed Uncover the already - diagnosed 1 Direct, bottom - up
Slide 15: ATR 1072 designed to silence mutant PRKAG2 to normalize AMPK activity
ATR 1072 designed to silence mutant PRKAG2 to normalize AMPK activity PRKAG2 is the regulatory Mutant PRKAG2 leads to Hypertrophic cardiomyopathy (HCM) characterized Mechanism component of AMPK overactivation of AMPK by glycogen accumulation and arrhythmia of Disease ATR 1072 - mediated degradation
Slide 16: ATR 1072 normalizes key cardiac functional measures in pre-clinical studies
ATR 1072 normalizes key cardiac functional measures in pre - clinical studies 1 Reduction of PRKAG2 at Day 28 Improvements in Cardiac Relaxation and Atrial Signaling following single dose of ATR 1072 at 24 weeks following 3 doses of ATR 1072 (3mg/kg) (3 mg/kg, q12w) P Wave Amplitude ATR 1072 ATR 107
Slide 17: ATR 1072 has a favorable preclinical safety profile and robust target knockdown
ATR 1072 has a favorable preclinical safety profile and robust target knockdown 1 ATR 1072 activity in monkey heart following a single dose at 28 days ATR 1072 was well tolerated in 9 - month, repeat of treatment dose chronic toxicity study in cynomolgus monkey PRKAG2 mRNA 150 • No dose limited toxi
Slide 18: ATR 1072: First trial targeting PRKAG2 syndrome with FPI by end of 2026
ATR 1072: First trial targeting PRKAG2 syndrome with FPI by end of 2026 Initial trial data demonstrating proof of concept anticipated in 2H 2027 48 - week treatment PART A - Dose Escalation PART B - Expansion Long Term Extension Cohort A1 Cohort A2 Cohort A3 Cohort B Long term 40 mg 80 mg 160 mg Rec
Slide 19: ATR 1086 PLN Cardiomyopathy
ATR 1086 PLN Cardiomyopathy 19
Slide 20: PLN Cardiomyopathy
PLN Cardiomyopathy A rare progressive disease with frequent family history • PLN - R14del is the most common disease - relevant PLN mutation 0 • Mutant PLN - R14del forms aggregates and impairs Approved cardiomyocyte function therapies • Characterized by dilated, arrhythmogenic or hypertrophic cardi
Slide 21: ATR 1086: Designed to silence mutant PLN to prevent protein aggregates
ATR 1086: Designed to silence mutant PLN to prevent protein aggregates and target root cause of disease 1 Phospholamban (PLN) regulates R14del mutation on PLN causes Dilated and Arrhythmogenic Mechanism Ca2+ handling in cardiomyocytes PLN to form protein aggregates cardiomyopathy (DCM & ACM) of Dise
Slide 22: ATR 1086 demonstrates functional improvement and survival in preclinical model of disease
ATR 1086 demonstrates functional improvement and survival in preclinical model of disease 1 Reduction of human PLN expression Improved survival (Kaplan - Meier survival curve) and ejection in the heart following treatment with fraction following repeated ATR 1086 treatment (6 mg/kg) in a A TR 1086 (
Slide 23: Expansion Opportunities for ATR 1072 and ATR 1086
Expansion Opportunities for ATR 1072 and ATR 1086 A biology driven pipeline with multiple indication expansion opportunities 23
Slide 24: ATR 1072 and ATR 1086 have opportunities for indication expansion
ATR 1072 and ATR 1086 have opportunities for indication expansion beyond a single genetically defined population Central Pathways in Opportunities for Cardiac Function Indication Expansion Energy sensing AMPK dysregulation is implicated across AMPK PRKAG2 regulates AMPK activity, ATR 1072 multiple g
Slide 25: Atrium is accelerating momentum post-launch, with multiple milestones over next 18 months
Atrium is accelerating momentum post - launch, with strong execution and multiple milestones over next 18 months Achievements Anticipated Upcoming Milestones • Pre- clinical proof - of- concept • First patient enrolled in Corventis Ph 1/2 trial by end of 2026 • GMP manufacturing ATR 1072 • Initial p
Slide 26: Atrium has the expertise, leadership and focused pipeline to deliver in precision cardiology
Atrium has the expertise, leadership and focused pipeline to deliver in precision cardiology Platfor m Pipeline Execution Proprietary RNA delivery Focused pipeline with Strong balance sheet with platform ideal for precision indication expansion experienced leadership cardiology opportunities team 26
Slide 27: IR Contact
IR Contact Stephanie Kenney, Chief Corporate Affairs Officer investors@atrium - tx.com 27
Atrium Therapeutics — Investor Presentation (August 2026) on 6ix